Overriding the Immune Evasion Tactics of Coronavirus
Overriding the Immune Evasion Tactics of Coronavirus
批准号:
10188930
负责人:
Carl F Ware
金额:
$61.8万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-08-12 至 2025-07-31
关键词:
2019-nCoVAgonistAntiviral AgentsBioinformaticsBiological AssayCOVID-19Cell LineCellsComplexCoronavirusCoronavirus InfectionsCritical PathwaysCytokine SignalingData AnalysesDefense MechanismsDiseaseDistalDrug DesignDrug ScreeningFacultyFuture GenerationsGene-ModifiedGeneticGenetic TranscriptionGenomeGoalsHost DefenseHumanImmune EvasionImmune responseImmune systemImmunologyInfectionInflammatoryInterferonsInterleukin-1KnowledgeLibrariesLifeLungLung infectionsMediatingModelingMurine hepatitis virusMusOrganOrganoidsOutcomePapainPathway interactionsPatientsPeptide HydrolasesPharmaceutical PreparationsPharmacologyPrincipal InvestigatorProductionProtein ChemistryProteinsProteomeProteomicsReporterRespiratory Tract InfectionsRoleScientistSignal PathwaySignal TransductionSystemTNF receptor-associated factor 3TestingTherapeuticTissuesVaccinesViralVirusVirus DiseasesVirus Replicationbiosafety level 3 facilitycytokinecytokine release syndromedesigndrug developmentevidence baseexperimental studygenome-wideherpesvirus entry mediatorhigh voltage electron microscopyimmunopathologyinhibitor/antagonistknowledge baselymphotoxin beta receptorlytic replicationnovelnovel therapeuticspandemic diseasepathogenprotein complexreceptorscreeningsuccesstooltranscriptometranscriptome sequencingtranscriptomicsvirology
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Progression of SARS-Coronavirus-2 (SARS-CoV-2) infected patients to life threatening disease may result from
a virus-mediated, dysregulated immune response associated with excessive production of inflammatory
cytokines, cytokine release syndrome. In this proposal we seek to identify therapeutics and knowledge of
Coronaviruses that will counteract the disruption in cytokine signaling pathways involved in effective host
defense.
We contribute to the urgent need for therapeutics that inhibit SARS-CoV-2 infection using pathway
specific reporter cells to screen for therapeutically active compounds that restore cytokine signaling. Our pathway
specific screens are a component in SBP-wide initiative to develop therapeutics that limit severe COVID-19. Our
screening strategy selects drugs identified in libraries of pharmacologically active therapeutics that block SARS-
CoV-2 lytic replication. We use cytokine pathway reporters to test these compounds in SARS-CoV-2 infection of
a lung cell line and human lung organoids in BSL3 facilities. The selected candidates will undergo analysis for
potential drug development.
Fundamental knowledge of cytokine-regulated defense mechanisms related to Coronavirus infection
limits the rational design of therapeutics and vaccines. To advance this knowledge we focus on the Lymphotoxin-
β Receptor (LTβR) and the Herpesvirus entry mediator (HVEM, TNFRSF14) pathways known to regulate anti-
viral cytokines, interferons (IFN) and interleukin-1(IL1β). Together, the LTβR and HVEM pathways act as an
integrated, homeostatic network that inhibits virus replication yet limits tissue damaging cytokines. Two SARS-
CoV-2 proteins, the Papain-like protease (PLPro, Nsp3) and Nsp9 target novel components in the TRAF3
interactome that control the NFκB transcriptome. We will determine the role of these components in the key
cytokine pathways using genetic and pharmacologic approaches in a mouse coronavirus lung infection model.
Together these two independent but complementary aims will provide an opportunity to help solve the SARS-
CoV-2 pandemic, and protect future generations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Overriding the Immune Evasion Tactics of Coronavirus
-
批准号:10237419
-
项目类别:
-
资助金额:$61.8万
-
财政年份:2020
-
负责人:Carl F Ware
-
依托单位:
Overriding the Immune Evasion Tactics of Coronavirus
-
批准号:10671613
-
项目类别:
-
资助金额:$60.16万
-
财政年份:2020
-
负责人:Carl F Ware
-
依托单位:
Overriding the Immune Evasion Tactics of Coronavirus
-
批准号:10454292
-
项目类别:
-
资助金额:$60.16万
-
财政年份:2020
-
负责人:Carl F Ware
-
依托单位:
HVEM-BTLA Pathway in Lymphoma
-
批准号:8700133
-
项目类别:
-
资助金额:$39.25万
-
财政年份:2012
-
负责人:Carl F Ware
-
依托单位:
HVEM-BTLA Pathway in Lymphoma
-
批准号:8534744
-
项目类别:
-
资助金额:$38.03万
-
财政年份:2012
-
负责人:Carl F Ware
-
依托单位:
HVEM-BTLA Pathway in Lymphoma
-
批准号:8370219
-
项目类别:
-
资助金额:$40.46万
-
财政年份:2012
-
负责人:Carl F Ware
-
依托单位:
HVEM-BTLA Pathway in Lymphoma
-
批准号:9081538
-
项目类别:
-
资助金额:$40.46万
-
财政年份:2012
-
负责人:Carl F Ware
-
依托单位:
MODULATING LYMPHOTOXINS IN PRIMATES FOR VIRAL DEFENSES
-
批准号:8357268
-
项目类别:
-
资助金额:$19.14万
-
财政年份:2011
-
负责人:Carl F Ware
-
依托单位:
Human Lymphoid Tissue Inducers
-
批准号:8136779
-
项目类别:
-
资助金额:$17.19万
-
财政年份:2010
-
负责人:Carl F Ware
-
依托单位:
MODULATING LYMPHOTOXINS IN PRIMATES FOR VIRAL DEFENSES
-
批准号:8172541
-
项目类别:
-
资助金额:$15.21万
-
财政年份:2010
-
负责人:Carl F Ware
-
依托单位:
Human Lymphoid Tissue Inducers
-
批准号:7874791
-
项目类别:
-
资助金额:$6.62万
-
财政年份:2010
-
负责人:Carl F Ware
-
依托单位:
Human Lymphoid Tissue Inducers
-
批准号:8020148
-
项目类别:
-
资助金额:$28.36万
-
财政年份:2010
-
负责人:Carl F Ware
-
依托单位:
MODULATING LYMPHOTOXINS IN PRIMATES FOR VIRAL DEFENSES
-
批准号:7959029
-
项目类别:
-
资助金额:$14.66万
-
财政年份:2009
-
负责人:Carl F Ware
-
依托单位:
HVEM-BTLA system in inflammation
-
批准号:8143923
-
项目类别:
-
资助金额:$37.25万
-
财政年份:2007
-
负责人:Carl F Ware
-
依托单位:
HVEM-BTLA system in Inflammation
-
批准号:8890072
-
项目类别:
-
资助金额:$48.0万
-
财政年份:2007
-
负责人:Carl F Ware
-
依托单位:
HVEM-BTLA system in inflammation
-
批准号:7848859
-
项目类别:
-
资助金额:$10.63万
-
财政年份:2007
-
负责人:Carl F Ware
-
依托单位:
HVEM-BTLA system in inflammation
-
批准号:7413616
-
项目类别:
-
资助金额:$46.55万
-
财政年份:2007
-
负责人:Carl F Ware
-
依托单位:
HVEM-BTLA system in inflammation
-
批准号:7264400
-
项目类别:
-
资助金额:$47.45万
-
财政年份:2007
-
负责人:Carl F Ware
-
依托单位:
HVEM-BTLA system in Inflammation
-
批准号:8507113
-
项目类别:
-
资助金额:$47.35万
-
财政年份:2007
-
负责人:Carl F Ware
-
依托单位:
HVEM-BTLA system in inflammation
-
批准号:7614417
-
项目类别:
-
资助金额:$46.55万
-
财政年份:2007
-
负责人:Carl F Ware
-
依托单位:
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
-
批准号:32000851
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:乔安娜
-
依托单位: